Profile - To The Moon

catzilla

Posts · 130Posts · 130
Following · 0Following · 0
Followers · 0Followers · 0

- catzillacatzilla
  ·2022-05-23
  Ok
  Abbott CEO Apologizes for Company's Role in Baby Formula Shortage
  Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company's role in the na
  Abbott CEO Apologizes for Company's Role in Baby Formula Shortage
  271 Comment
  Like
  Share
  Report
- catzillacatzilla
  ·2022-05-23
  Ok
  Biotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential
  While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safe
  Biotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential
  288 Comment
  1
  Share
  Report
- catzillacatzilla
  ·2021-09-24
  $Philip Morris(PM)$PM
  204 Comment
  1
  Share
  Report
- catzillacatzilla
  ·2021-09-23
  $Shopify(SHOP)$ lets go shopping
  350 1
  1
  Share
  Report
- catzillacatzilla
  ·2021-09-20
  $BlackBerry(BB)$ lousy stock
  387 Comment
  2
  Share
  Report
- catzillacatzilla
  ·2021-09-20
  $Shopify(SHOP)$ lets shop
  339 Comment
  Like
  Share
  Report
- catzillacatzilla
  ·2021-09-17
  $Visa(V)$V
  219 Comment
  Like
  Share
  Report
- catzillacatzilla
  ·2021-09-15
  $Walt Disney(DIS)$disney
  498 Comment
  Like
  Share
  Report
- catzillacatzilla
  ·2021-09-14
  $iRobot(IRBT)$robot
  544 Comment
  Like
  Share
  Report
- catzillacatzilla
  ·2021-09-11
  $Shopify(SHOP)$ share share
  571 1
  1
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4087904141293090","uuid":"4087904141293090","gmtCreate":1624801351629,"gmtModify":1624845976839,"name":"catzilla","pinyin":"catzilla","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":393,"tweetSize":130,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9028707103,"gmtCreate":1653272958302,"gmtModify":1676535251947,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9028707103","repostId":"2237084564","repostType":4,"repost":{"id":"2237084564","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1653269638,"share":"https://ttm.financial/m/news/2237084564?lang=&edition=fundamental","pubTime":"2022-05-23 09:33","market":"us","language":"en","title":"Abbott CEO Apologizes for Company's Role in Baby Formula Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2237084564","media":"Dow Jones","summary":"Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company's role in the na","content":"<html><head></head><body><p>Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company&#39;s role in the nationwide shortage of baby formula and promised production will ramp up again in June.</p><p>&#34;We&#39;re sorry to every family we&#39;ve let down,&#34; Mr. Ford wrote in a Washington Post op-ed.</p><p>Mr. Ford explained what led to his company&#39;s voluntary recall of baby formula and detailed the company&#39;s plan to avoid a similar shortage in the future.</p><p>&#34;We are making significant investments to ensure this never happens again,&#34; he wrote.</p><p>In February, Abbott Laboratories voluntarily recalled some of its Similac, Alimentum and EleCare formulas manufactured in its Sturgis, Mich., plant after Food and Drug Administration officials found a potentially deadly bacteria there.</p><p>That decision exacerbated an existing baby formula shortage created by supply-chain issues during the Covid-19 pandemic, Mr. Ford acknowledged.</p><p>&#34;We take great pride in manufacturing nutrition and formula to feed America&#39;s infants, including our most vulnerable,&#34; Mr. Ford said.</p><p>&#34;But the past few months have distressed us as they have you, and so I want to say: We&#39;re sorry to every family we&#39;ve let down since our voluntary recall exacerbated our nation&#39;s baby formula shortage,&#34; he said.</p><p>Four infants who drank tainted baby formula were hospitalized and two of them died, however the FDA said the bacteria didn&#39;t match the strains found at the Abbott plant.</p><p>Nonetheless, Mr. Ford wrote, issuing a voluntary recall was the right thing to do.</p><p>&#34;The FDA&#39;s investigation did discover a bacteria in our plant that we will not tolerate. I have high expectations of this company, and we fell short of them,&#34; he wrote. &#34;We will not take risks when it comes to the health of children.&#34;</p><p>The shortage has led to empty shelves at some stores, product restrictions and panic among parents and caregivers searching for formula to feed their babies.</p><p>President Biden on Wednesday invoked the Defense Production Act to increase production of baby formula and launched a program -- called Operation Fly Formula -- that would bring supplies by cargo plane that meets U.S. standards from overseas.</p><p>On Sunday, Mr. Biden  tweeted photos of the aircraft being loaded with supplies.</p><p>&#34;Our team is working around the clock to get safe formula to everyone who needs it,&#34; Mr. Biden wrote on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>, moments before the first formula shipment arrived in Indiana Sunday.</p><p>A top White House official on Sunday defended the administration&#39;s approach to the shortage and blamed longer-term trends for the crisis.</p><p>&#34;How did we end up in a market where we have three companies that control 90% of the market?&#34; the director of the White House National Economic Council, Brian Deese, said on CNN&#39;s &#34;State of the Union,&#34; adding that officials were weighing steps to open up that market to more competition.</p><p>&#34;We&#39;re going to have to work on that,&#34; Mr. Deese said.</p><p>Mr. Deese also said that the first shipment of formula brought to Indiana from Germany accounted for around 15% of the national need, and that he expected additional such flights early this week.</p><p>&#34;We&#39;re going to keep ramping that up until we get there,&#34; he said.</p><p>Abbott&#39;s Mr. Ford said the company plans to restart its Sturgis facility in early June after entering into a consent decree with the FDA. It will take six to eight weeks from when production begins to get products on the shelves.</p><p>&#34;When we are operating our Michigan facility at full capacity, we will more than double our current production of powdered infant formula for the United States,&#34; he wrote. &#34;By the end of June, we will be supplying more formula to Americans than we were in January before the recall.&#34;</p><p>Meanwhile, he said, the company is putting baby formula production ahead of all its other adult products at its Ohio plant and has flown in supplies from its facility in Ireland.</p><p>Specialized baby formula known as EleCare, for infants or children who can&#39;t digest other formulas and milks, is the priority, Mr. Ford said.</p><p>&#34;Given their unique needs, children who lose access to it can require medical supervision until the formula is returned to the shelves,&#34; he wrote.</p><p>Consumers can feel safe buying Abbott Laboratories products currently in stores, Mr. Ford said.</p><p>&#34;What is available has passed rigorous inspections and is ready for your babies,&#34; he said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott CEO Apologizes for Company's Role in Baby Formula Shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott CEO Apologizes for Company's Role in Baby Formula Shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-05-23 09:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company&#39;s role in the nationwide shortage of baby formula and promised production will ramp up again in June.</p><p>&#34;We&#39;re sorry to every family we&#39;ve let down,&#34; Mr. Ford wrote in a Washington Post op-ed.</p><p>Mr. Ford explained what led to his company&#39;s voluntary recall of baby formula and detailed the company&#39;s plan to avoid a similar shortage in the future.</p><p>&#34;We are making significant investments to ensure this never happens again,&#34; he wrote.</p><p>In February, Abbott Laboratories voluntarily recalled some of its Similac, Alimentum and EleCare formulas manufactured in its Sturgis, Mich., plant after Food and Drug Administration officials found a potentially deadly bacteria there.</p><p>That decision exacerbated an existing baby formula shortage created by supply-chain issues during the Covid-19 pandemic, Mr. Ford acknowledged.</p><p>&#34;We take great pride in manufacturing nutrition and formula to feed America&#39;s infants, including our most vulnerable,&#34; Mr. Ford said.</p><p>&#34;But the past few months have distressed us as they have you, and so I want to say: We&#39;re sorry to every family we&#39;ve let down since our voluntary recall exacerbated our nation&#39;s baby formula shortage,&#34; he said.</p><p>Four infants who drank tainted baby formula were hospitalized and two of them died, however the FDA said the bacteria didn&#39;t match the strains found at the Abbott plant.</p><p>Nonetheless, Mr. Ford wrote, issuing a voluntary recall was the right thing to do.</p><p>&#34;The FDA&#39;s investigation did discover a bacteria in our plant that we will not tolerate. I have high expectations of this company, and we fell short of them,&#34; he wrote. &#34;We will not take risks when it comes to the health of children.&#34;</p><p>The shortage has led to empty shelves at some stores, product restrictions and panic among parents and caregivers searching for formula to feed their babies.</p><p>President Biden on Wednesday invoked the Defense Production Act to increase production of baby formula and launched a program -- called Operation Fly Formula -- that would bring supplies by cargo plane that meets U.S. standards from overseas.</p><p>On Sunday, Mr. Biden  tweeted photos of the aircraft being loaded with supplies.</p><p>&#34;Our team is working around the clock to get safe formula to everyone who needs it,&#34; Mr. Biden wrote on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>, moments before the first formula shipment arrived in Indiana Sunday.</p><p>A top White House official on Sunday defended the administration&#39;s approach to the shortage and blamed longer-term trends for the crisis.</p><p>&#34;How did we end up in a market where we have three companies that control 90% of the market?&#34; the director of the White House National Economic Council, Brian Deese, said on CNN&#39;s &#34;State of the Union,&#34; adding that officials were weighing steps to open up that market to more competition.</p><p>&#34;We&#39;re going to have to work on that,&#34; Mr. Deese said.</p><p>Mr. Deese also said that the first shipment of formula brought to Indiana from Germany accounted for around 15% of the national need, and that he expected additional such flights early this week.</p><p>&#34;We&#39;re going to keep ramping that up until we get there,&#34; he said.</p><p>Abbott&#39;s Mr. Ford said the company plans to restart its Sturgis facility in early June after entering into a consent decree with the FDA. It will take six to eight weeks from when production begins to get products on the shelves.</p><p>&#34;When we are operating our Michigan facility at full capacity, we will more than double our current production of powdered infant formula for the United States,&#34; he wrote. &#34;By the end of June, we will be supplying more formula to Americans than we were in January before the recall.&#34;</p><p>Meanwhile, he said, the company is putting baby formula production ahead of all its other adult products at its Ohio plant and has flown in supplies from its facility in Ireland.</p><p>Specialized baby formula known as EleCare, for infants or children who can&#39;t digest other formulas and milks, is the priority, Mr. Ford said.</p><p>&#34;Given their unique needs, children who lose access to it can require medical supervision until the formula is returned to the shelves,&#34; he wrote.</p><p>Consumers can feel safe buying Abbott Laboratories products currently in stores, Mr. Ford said.</p><p>&#34;What is available has passed rigorous inspections and is ready for your babies,&#34; he said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237084564","content_text":"Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company's role in the nationwide shortage of baby formula and promised production will ramp up again in June.\"We're sorry to every family we've let down,\" Mr. Ford wrote in a Washington Post op-ed.Mr. Ford explained what led to his company's voluntary recall of baby formula and detailed the company's plan to avoid a similar shortage in the future.\"We are making significant investments to ensure this never happens again,\" he wrote.In February, Abbott Laboratories voluntarily recalled some of its Similac, Alimentum and EleCare formulas manufactured in its Sturgis, Mich., plant after Food and Drug Administration officials found a potentially deadly bacteria there.That decision exacerbated an existing baby formula shortage created by supply-chain issues during the Covid-19 pandemic, Mr. Ford acknowledged.\"We take great pride in manufacturing nutrition and formula to feed America's infants, including our most vulnerable,\" Mr. Ford said.\"But the past few months have distressed us as they have you, and so I want to say: We're sorry to every family we've let down since our voluntary recall exacerbated our nation's baby formula shortage,\" he said.Four infants who drank tainted baby formula were hospitalized and two of them died, however the FDA said the bacteria didn't match the strains found at the Abbott plant.Nonetheless, Mr. Ford wrote, issuing a voluntary recall was the right thing to do.\"The FDA's investigation did discover a bacteria in our plant that we will not tolerate. I have high expectations of this company, and we fell short of them,\" he wrote. \"We will not take risks when it comes to the health of children.\"The shortage has led to empty shelves at some stores, product restrictions and panic among parents and caregivers searching for formula to feed their babies.President Biden on Wednesday invoked the Defense Production Act to increase production of baby formula and launched a program -- called Operation Fly Formula -- that would bring supplies by cargo plane that meets U.S. standards from overseas.On Sunday, Mr. Biden  tweeted photos of the aircraft being loaded with supplies.\"Our team is working around the clock to get safe formula to everyone who needs it,\" Mr. Biden wrote on Twitter, moments before the first formula shipment arrived in Indiana Sunday.A top White House official on Sunday defended the administration's approach to the shortage and blamed longer-term trends for the crisis.\"How did we end up in a market where we have three companies that control 90% of the market?\" the director of the White House National Economic Council, Brian Deese, said on CNN's \"State of the Union,\" adding that officials were weighing steps to open up that market to more competition.\"We're going to have to work on that,\" Mr. Deese said.Mr. Deese also said that the first shipment of formula brought to Indiana from Germany accounted for around 15% of the national need, and that he expected additional such flights early this week.\"We're going to keep ramping that up until we get there,\" he said.Abbott's Mr. Ford said the company plans to restart its Sturgis facility in early June after entering into a consent decree with the FDA. It will take six to eight weeks from when production begins to get products on the shelves.\"When we are operating our Michigan facility at full capacity, we will more than double our current production of powdered infant formula for the United States,\" he wrote. \"By the end of June, we will be supplying more formula to Americans than we were in January before the recall.\"Meanwhile, he said, the company is putting baby formula production ahead of all its other adult products at its Ohio plant and has flown in supplies from its facility in Ireland.Specialized baby formula known as EleCare, for infants or children who can't digest other formulas and milks, is the priority, Mr. Ford said.\"Given their unique needs, children who lose access to it can require medical supervision until the formula is returned to the shelves,\" he wrote.Consumers can feel safe buying Abbott Laboratories products currently in stores, Mr. Ford said.\"What is available has passed rigorous inspections and is ready for your babies,\" he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9028704409,"gmtCreate":1653272941301,"gmtModify":1676535251946,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9028704409","repostId":"1182237011","repostType":4,"repost":{"id":"1182237011","pubTimestamp":1653271586,"share":"https://ttm.financial/m/news/1182237011?lang=&edition=fundamental","pubTime":"2022-05-23 10:06","market":"us","language":"en","title":"Biotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1182237011","media":"24/7 wall street","summary":"While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safe","content":"<html><head></head><body><p>While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.</p><p>Many investors, especially more aggressive traders, look at lower-priced stocks as a way not only to make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.</p><p>Goldman Sachs is the premier investment bank in the world, so we screened its outstanding research database and found five stocks trading under the $10 level that could provide investors with upside potential ranging from over 125% to 400%. For those leery of low-priced shares, just remember that Amazon and Apple at one time traded in the single digits. Zynga, a stock we have featured over the years, recently was purchased by Take-Two Interactive Software.</p><p>While all five are rated Buy at Goldman Sachs, they are much better suited for very aggressive investors. It also is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.</p><p><b>Farfetch</b></p><p>This stock traded in the $50s a year ago and now has a huge upside. Farfetch Ltd. (NYSE: FTCH) provides an online marketplace for luxury fashion goods in the United States, the United Kingdom and elsewhere.</p><p>Besides operating Farfetch.com, an online marketplace, and the Farfetch app for retailers and brands, the company also offers web design, build, development and retail distribution solutions for retailers and brands. As of December 31, 2021, operated two Browns retail stores; two Stadium Goods retail stores; and 12 New Guards Off-White stores, three Ambush stores, two Palm Angels stores and three Off-White outlets. In addition, it operates approximately 60 New Guards franchised retail stores and four seasonal stores under various brands.</p><p>The $45 Goldman Sachs target price is well above the $30.58 consensus target. The shares closed on Friday at $7.86, so hitting the Goldman Sachs target would be a 475% or so gain.</p><p><b>Kronos Bio</b></p><p>This microcap biotech may be the biggest winner of all the Goldman Sachs Buy-rated stocks under $10. Kronos Bio Inc. (NASDAQ: KRON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics.</p><p>The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, which is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.</p><p>The company’s planned registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in Phase 1/2 clinical trial.</p><p>Goldman Sachs has set a price target of $35 per share, and the consensus target is even higher at $40.25. Hitting the Goldman Sachs target would be a more than 800% gain from the recent friday share price close of $3.81.</p><p><b>Lyell Immunopharma</b></p><p>This microcap biotech also could be a huge home run aggressive traders. Lyell Immunopharma (NASDAQ: LYEL) is a T cell reprogramming company engaged in developing T cell therapies for patients with solid tumors.</p><p>The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming technology to generate a population of T cells with durable stemness.</p><p>Lyell Immunopharma’s pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.</p><p>The Goldman Sachs price target is $21, while the consensus target is $22. The shares closed trading at $4.11 on Friday, hitting the Goldman Sachs target would be a gain of about 450%.</p><p><b>Taysha Gene Therapies</b></p><p>This company went public in 2020 and was trading close to $30 a share before it was clobbered. Taysha Gene Therapies Inc. (NASDAQ: TSHA) focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system, including the following:</p><ul><li>TSHA-120 for the treatment of giant axonal neuropathy</li><li>TSHA-102 for the treatment of Rett syndrome</li><li>TSHA-121 for the treatment of CLN1 disease</li><li>TSHA-118 for the treatment of CLN1 disease</li><li>TSHA-105 for the treatment of SLC13A5 deficiency</li><li>TSHA-101 for the treatment of GM2 gangliosidosis</li></ul><p>Goldman Sachs has a $27 target price. The $25.50 consensus target is also well above the final share price of $2.77 seen on Friday. The Goldman Sachs target represents about a 790% gain.</p><p><b>Zevia PBC</b></p><p>This is another micro-cap idea with incredible upside potential. Zevia PBC (NYSE: ZVIA) is a beverage company that develops, markets, sells and distributes various carbonated and non-carbonated soft drinks in the United States and Canada.</p><p>Its products include soda, energy drinks, organic tea, mixers, kidz beverages and sparkling water under the Zevia brand name. The company offers its products through various retail channels, including grocery distributors, national retailers, warehouse club and natural products retailers, as well as e-commerce channels.</p><p>The company is focused on addressing the global health challenges resulting from excess sugar consumption by offering a broad portfolio of zero sugar, zero calorie, naturally sweetened beverages. All Zevia beverages are made with a handful of simple, plant-based ingredients, contain no artificial sweeteners and are Non-GMO Project verified, gluten-free, Kosher, vegan and zero sodium.</p><p>The $14 price target at Goldman Sachs compares with an $11.27 consensus target and Friday’s closing share price of $1.99. Hitting the Goldman Sachs target would be a 550% gain.</p><p>These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.</p></body></html>","source":"lsy1620372341666","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-23 10:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://247wallst.com/investing/2022/05/21/biotech-dominates-goldman-sachs-5-buy-rated-stocks-under-10-with-400-to-800-upside-potential/><strong>24/7 wall street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the ...</p>\n\n<a href=\"https://247wallst.com/investing/2022/05/21/biotech-dominates-goldman-sachs-5-buy-rated-stocks-under-10-with-400-to-800-upside-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LYEL":"Lyell Immunopharma, Inc.","ZVIA":"Zevia PBC","KRON":"Kronos Bio, Inc.","TSHA":"Taysha Gene Therapies, Inc."},"source_url":"https://247wallst.com/investing/2022/05/21/biotech-dominates-goldman-sachs-5-buy-rated-stocks-under-10-with-400-to-800-upside-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182237011","content_text":"While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.Many investors, especially more aggressive traders, look at lower-priced stocks as a way not only to make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.Goldman Sachs is the premier investment bank in the world, so we screened its outstanding research database and found five stocks trading under the $10 level that could provide investors with upside potential ranging from over 125% to 400%. For those leery of low-priced shares, just remember that Amazon and Apple at one time traded in the single digits. Zynga, a stock we have featured over the years, recently was purchased by Take-Two Interactive Software.While all five are rated Buy at Goldman Sachs, they are much better suited for very aggressive investors. It also is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.FarfetchThis stock traded in the $50s a year ago and now has a huge upside. Farfetch Ltd. (NYSE: FTCH) provides an online marketplace for luxury fashion goods in the United States, the United Kingdom and elsewhere.Besides operating Farfetch.com, an online marketplace, and the Farfetch app for retailers and brands, the company also offers web design, build, development and retail distribution solutions for retailers and brands. As of December 31, 2021, operated two Browns retail stores; two Stadium Goods retail stores; and 12 New Guards Off-White stores, three Ambush stores, two Palm Angels stores and three Off-White outlets. In addition, it operates approximately 60 New Guards franchised retail stores and four seasonal stores under various brands.The $45 Goldman Sachs target price is well above the $30.58 consensus target. The shares closed on Friday at $7.86, so hitting the Goldman Sachs target would be a 475% or so gain.Kronos BioThis microcap biotech may be the biggest winner of all the Goldman Sachs Buy-rated stocks under $10. Kronos Bio Inc. (NASDAQ: KRON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics.The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, which is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.The company’s planned registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in Phase 1/2 clinical trial.Goldman Sachs has set a price target of $35 per share, and the consensus target is even higher at $40.25. Hitting the Goldman Sachs target would be a more than 800% gain from the recent friday share price close of $3.81.Lyell ImmunopharmaThis microcap biotech also could be a huge home run aggressive traders. Lyell Immunopharma (NASDAQ: LYEL) is a T cell reprogramming company engaged in developing T cell therapies for patients with solid tumors.The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming technology to generate a population of T cells with durable stemness.Lyell Immunopharma’s pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.The Goldman Sachs price target is $21, while the consensus target is $22. The shares closed trading at $4.11 on Friday, hitting the Goldman Sachs target would be a gain of about 450%.Taysha Gene TherapiesThis company went public in 2020 and was trading close to $30 a share before it was clobbered. Taysha Gene Therapies Inc. (NASDAQ: TSHA) focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system, including the following:TSHA-120 for the treatment of giant axonal neuropathyTSHA-102 for the treatment of Rett syndromeTSHA-121 for the treatment of CLN1 diseaseTSHA-118 for the treatment of CLN1 diseaseTSHA-105 for the treatment of SLC13A5 deficiencyTSHA-101 for the treatment of GM2 gangliosidosisGoldman Sachs has a $27 target price. The $25.50 consensus target is also well above the final share price of $2.77 seen on Friday. The Goldman Sachs target represents about a 790% gain.Zevia PBCThis is another micro-cap idea with incredible upside potential. Zevia PBC (NYSE: ZVIA) is a beverage company that develops, markets, sells and distributes various carbonated and non-carbonated soft drinks in the United States and Canada.Its products include soda, energy drinks, organic tea, mixers, kidz beverages and sparkling water under the Zevia brand name. The company offers its products through various retail channels, including grocery distributors, national retailers, warehouse club and natural products retailers, as well as e-commerce channels.The company is focused on addressing the global health challenges resulting from excess sugar consumption by offering a broad portfolio of zero sugar, zero calorie, naturally sweetened beverages. All Zevia beverages are made with a handful of simple, plant-based ingredients, contain no artificial sweeteners and are Non-GMO Project verified, gluten-free, Kosher, vegan and zero sodium.The $14 price target at Goldman Sachs compares with an $11.27 consensus target and Friday’s closing share price of $1.99. Hitting the Goldman Sachs target would be a 550% gain.These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863427192,"gmtCreate":1632415321216,"gmtModify":1676530778168,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PM\">$Philip Morris(PM)$</a>PM","listText":"<a href=\"https://laohu8.com/S/PM\">$Philip Morris(PM)$</a>PM","text":"$Philip Morris(PM)$PM","images":[{"img":"https://static.tigerbbs.com/539be238b70da26b9c542f218ba3ca53","width":"720","height":"1679"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863427192","isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":863092097,"gmtCreate":1632327341719,"gmtModify":1676530755005,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SHOP\">$Shopify(SHOP)$</a>&nbsp;lets go shopping","listText":"<a href=\"https://laohu8.com/S/SHOP\">$Shopify(SHOP)$</a>&nbsp;lets go shopping","text":"$Shopify(SHOP)$ lets go shopping","images":[{"img":"https://static.tigerbbs.com/aaa59a5a15caa5668c0b622f41506078","width":"720","height":"1679"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/863092097","isVote":1,"tweetType":1,"viewCount":350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":860079659,"gmtCreate":1632112448971,"gmtModify":1676530703674,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>&nbsp;lousy stock","listText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a>&nbsp;lousy stock","text":"$BlackBerry(BB)$ lousy stock","images":[{"img":"https://static.tigerbbs.com/4d7f3fd4d968ebe868074eb262a4180b","width":"720","height":"1745"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860079659","isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":887528997,"gmtCreate":1632068274119,"gmtModify":1676530695233,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SHOP\">$Shopify(SHOP)$</a>&nbsp;lets shop","listText":"<a href=\"https://laohu8.com/S/SHOP\">$Shopify(SHOP)$</a>&nbsp;lets shop","text":"$Shopify(SHOP)$ lets shop","images":[{"img":"https://static.tigerbbs.com/2b739a972e5ca44f2933d3d0514b9290","width":"720","height":"1745"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887528997","isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":884084566,"gmtCreate":1631840138255,"gmtModify":1676530648936,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/V\">$Visa(V)$</a>V","listText":"<a href=\"https://laohu8.com/S/V\">$Visa(V)$</a>V","text":"$Visa(V)$V","images":[{"img":"https://static.tigerbbs.com/4273788c19e569ad02e55c7c38ad58ef","width":"720","height":"1745"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884084566","isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":882413795,"gmtCreate":1631714265217,"gmtModify":1676530616236,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>disney","listText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>disney","text":"$Walt Disney(DIS)$disney","images":[{"img":"https://static.tigerbbs.com/f48a11c0881d6f80ab61a2c1cd026118","width":"720","height":"1679"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882413795","isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":886471365,"gmtCreate":1631621734057,"gmtModify":1676530591835,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IRBT\">$iRobot(IRBT)$</a>robot","listText":"<a href=\"https://laohu8.com/S/IRBT\">$iRobot(IRBT)$</a>robot","text":"$iRobot(IRBT)$robot","images":[{"img":"https://static.tigerbbs.com/b7ab38b75d1051ba1f7950993edfc866","width":"720","height":"1745"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886471365","isVote":1,"tweetType":1,"viewCount":544,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":881271768,"gmtCreate":1631353147754,"gmtModify":1676530534530,"author":{"id":"4087904141293090","authorId":"4087904141293090","name":"catzilla","avatar":"https://static.tigerbbs.com/08e6f2b0810c3d8fff459803d35fc362","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087904141293090","authorIdStr":"4087904141293090"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SHOP\">$Shopify(SHOP)$</a>&nbsp;share share","listText":"<a href=\"https://laohu8.com/S/SHOP\">$Shopify(SHOP)$</a>&nbsp;share share","text":"$Shopify(SHOP)$ share share","images":[{"img":"https://static.tigerbbs.com/d123c71dbdf9b9e2d0116659e593b847","width":"720","height":"1745"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881271768","isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}